ABSTRACT OF THE WEEK

The Veterinary Clinics of North America. Food animal practice
Volume 37 | Issue 3 (November 2021)

Registered Medicinal Products for Use in Honey Bees in the United States and Canada.

Vet Clin North Am Food Anim Pract. November 2021;37(3):451-465.

Tracy S Farone¹

¹ Grove City College, 100 Campus Drive, Grove City, PA 16127, USA. Electronic address: tsfarone@gcc.edu.

Abstract

A 2017 US Food and Drug Administration mandate requiring veterinary oversight for medically important antibiotics used in agricultural animals, including honey bees (Apis mellifera L.) created a "new" animal requiring veterinary involvement. Many resources are available describing medical formulations of antibiotics and other drugs used in the treatment of various honey bee maladies. The goal of this article is to summarize this information in an up-to-date, practical way for the clinician. At the time of this writing, only 3 antibiotics are approved for use in honey bees and require veterinary prescriptions or veterinary feed directives.

Keywords

Antibiotic resistance; Honey bee antibiotics; Veterinary feed directive (VFD); Veterinary honey bee medications;

Article Tools:

Medline

Email to me

Archives Highlights:

Topical and oral emodepside formulations for last-line treatment of multianthelmintic drug-resistant hookworms when given orally to dogs are not bioequivalent.
This study was conducted in 3 phases, during which dogs received single doses of emodepside as the feline topical solution (1 mg/kg) orally, the canine modified-release tablet (1 mg/kg) orally, and the topical feline solution (3 mg/kg) topically. The feline topical solution administered orally at 1 mg/kg is not bioequivalent to the canine modified-release tablet. Markedly higher absorption of the feline topical solution administered orally raises potential safety concerns for extra-label use in dogs to treat multi-anthelmintic drug-resistant hookworm infections. Poor absorption following topical administration suggests it may be unsuitable for treating multi-anthelmintic drug-resistant hookworm infections.

How to plan and provide general anesthesia for a troop of 98 hamadryas baboons (Papio hamadryas) for contraceptive and preventative health interventions.
A group of 12 veterinarians, 2 zookeepers, and 6 volunteers anesthetized all animals within 2 days. The baboons were orally premedicated with midazolam (0.1 to 0.5 mg/kg) and anesthetized with medetomidine (40 to 60 µg/kg, IM) and ketamine (2 to 4 mg/kg, IM); isoflurane at rates of 1.5% to 2% was used for maintaining anesthesia if necessary. For population management, the animals received a contraceptive implant (adult females), orchiectomy (young males), or vasectomy (breeding males).

Limb amputation for feline appendicular bone tumors results in excellent recovery outcomes and high owner satisfaction with a low incidence of complications.
Time to return to walking without support was < 3 days in 69.7% of cats and 3 to 7 days in 16.7%. Activity level changes were reported as no change in 75.8% of cats. There were no behavioral changes in 92.3% of cats. Quality of life following amputation was recorded as excellent in 82.4% of cats. Owner satisfaction was reported as very satisfied, moderately satisfied, or satisfied in 98.5% of cats.

Retrospective cohort study on diseases and risk factors associated with death in hospitalized neonatal foals.
Most prevalent diseases were sepsis (43.9%), enteritis (14.0%), and omphalitis (9.0%). Case fatality rate was 33.3%. Neonatal sepsis significantly increased the risk of death.

The 4 prokinetic drugs metoclopramide, cisapride, pyridostigmine, and capromorelin do not increase fecal output or food intake in healthy New Zealand rabbits (Oryctolagus cuniculus).
Every day, rabbits produced a median of 75 g (range, 9 to 145 g) of feces, 226 fecal pellets (range, 12 to 412 pellets), and 151 mL (range, 5 to 420 mL) of urine. Metoclopramide, cisapride, pyridostigmine, and capromorelin had no effect on fecal production (both weight and number of pellets), food intake, urine production, or water intake compared to placebo at 24, 48, or 72 hours after administration.